The recent clinical success of treating “Baby KJ” Muldoon—an infant born with a rare metabolic disease—with the first-ever personalized gene-editing therapy brought much-needed enthusiasm to the ...
UCSF Benioff Children’s Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results